Chinese VCs continue to thrive on the European Healthcare market

Investors from China continue to show exceptional interest in young life science companies based in Europe.

Investments made by Chinese VCs have significantly grown 17-fold over the last five years (from EUR 34m in 2017 to EUR 592m in 2021).

The top investor were Morningside Group investing EUR 225m in fourteen deals, followed by Tencent Holdings (EUR 194m) in seven deals and the Ally Bridge Group (EUR 92m) in three deals.

The observed trend indicates increasing interest in European healthcare technologies by Chinese VCs.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: